Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000155,BN/SsNHsd,not specified,91 days,6,,CMO:0001622,percentage of study population developing pituitary gland hyperplastic lesions during a period of time,,,,100,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69908,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,not specified,91 days,6,,CMO:0001622,percentage of study population developing pituitary gland hyperplastic lesions during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69912,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0001297,F344.BN-(D5Rat1-D5Mit5)/Dlw,not specified,91 days,6,,CMO:0001622,percentage of study population developing pituitary gland hyperplastic lesions during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69916,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000155,BN/SsNHsd,not specified,91 days,6,,CMO:0001618,percentage of study population developing pituitary tumors that replace a portion of the gland during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69909,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,not specified,91 days,6,,CMO:0001618,percentage of study population developing pituitary tumors that replace a portion of the gland during a period of time,,,,50,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69913,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0001297,F344.BN-(D5Rat1-D5Mit5)/Dlw,not specified,91 days,6,,CMO:0001618,percentage of study population developing pituitary tumors that replace a portion of the gland during a period of time,,,,67,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69917,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000155,BN/SsNHsd,not specified,91 days,6,,CMO:0001617,percentage of study population developing pituitary tumors that replace the entire gland during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69910,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,not specified,91 days,6,,CMO:0001617,percentage of study population developing pituitary tumors that replace the entire gland during a period of time,,,,50,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69914,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0001297,F344.BN-(D5Rat1-D5Mit5)/Dlw,not specified,91 days,6,,CMO:0001617,percentage of study population developing pituitary tumors that replace the entire gland during a period of time,,,,33,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69918,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000155,BN/SsNHsd,not specified,91 days,6,,CMO:0001619,percentage of study population developing pituitary tumors that invade the glandular capsule during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69911,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,not specified,91 days,6,,CMO:0001619,percentage of study population developing pituitary tumors that invade the glandular capsule during a period of time,,,,50,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69915,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0001297,F344.BN-(D5Rat1-D5Mit5)/Dlw,not specified,91 days,6,,CMO:0001619,percentage of study population developing pituitary tumors that invade the glandular capsule during a period of time,,,,67,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69919,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 331,"Shull JD, et al., Mamm Genome. 2007 Sep 18;.",pituitary gland mass,,RS:0000032,ACI/SegHsd,female,266 days to 252 days,9,,CMO:0000853,pituitary gland wet weight,,,,0.1459,g,0.0119,0.0358,MMO:0000005,post excision weight measurement,pituitary gland,0,,,,,surgical implantation then 17 beta-estradiol (27.5 mg) (between 193 and 199 days),13093,surgical implantation,,17 beta-estradiol (27.5 mg) (between 193 and 199 days) 331,"Shull JD, et al., Mamm Genome. 2007 Sep 18;.",pituitary gland mass,,RS:0000155,BN/SsNHsd,female,266 days to 252 days,10,,CMO:0000853,pituitary gland wet weight,,,,0.0139,g,6.0E-4,0.002,MMO:0000005,post excision weight measurement,pituitary gland,0.0,,,,,surgical implantation then 17 beta-estradiol (27.5 mg) (between 193 and 199 days),13102,surgical implantation,,17 beta-estradiol (27.5 mg) (between 193 and 199 days) 1122,"Strecker TE, et al., Genetics 2005 Jan 31;.",pituitary gland mass,,RS:0000032,ACI/SegHsd,male,147 days,14,,CMO:0000853,pituitary gland wet weight,,,,0.0817,g,0.0028,0.0103,MMO:0000005,post excision weight measurement,,0.0,diethylstilbestrol,subcutaneous implant,84,days,diethylstilbestrol (5 mg) (for 84 days) and surgical implantation,69101,diethylstilbestrol (5 mg) (for 84 days),surgical implantation, 1122,"Strecker TE, et al., Genetics 2005 Jan 31;.",pituitary gland mass,,RS:0000185,COP/CrCrl,male,147 days,14,,CMO:0000853,pituitary gland wet weight,,,,0.0342,g,0.0016,0.0059,MMO:0000005,post excision weight measurement,,0.0,diethylstilbestrol,subcutaneous implant,84,days,diethylstilbestrol (5 mg) (for 84 days) and surgical implantation,69103,diethylstilbestrol (5 mg) (for 84 days),surgical implantation, 1122,"Strecker TE, et al., Genetics 2005 Jan 31;.",pituitary gland mass,,RS:0000032,ACI/SegHsd,male,147 days,28,,CMO:0000853,pituitary gland wet weight,,,,0.0727,g,0.0028,0.0146,MMO:0000005,post excision weight measurement,,0.0,diethylstilbestrol,subcutaneous implant,84,days,diethylstilbestrol (5 mg) (for 84 days) and surgical implantation,69105,diethylstilbestrol (5 mg) (for 84 days),surgical implantation, 1122,"Strecker TE, et al., Genetics 2005 Jan 31;.",pituitary gland mass,,RS:0000185,COP/CrCrl,male,147 days,28,,CMO:0000853,pituitary gland wet weight,,,,0.0362,g,0.0014,0.0074,MMO:0000005,post excision weight measurement,,0.0,diethylstilbestrol,subcutaneous implant,84,days,diethylstilbestrol (5 mg) (for 84 days) and surgical implantation,69107,diethylstilbestrol (5 mg) (for 84 days),surgical implantation, 1121,"Gould KA, et al., Mamm Genome. 2006 May;17(5):451-64.",thymus mass,,RS:0000155,BN/SsNHsd,male,147 days,15,,CMO:0000855,thymus wet weight,,,,66,mg,4.3894,17.0,MMO:0000005,post excision weight measurement,,0.0,diethylstilbestrol,subcutaneous implant,84,days,diethylstilbestrol (5 mg) (for 84 days) and surgical implantation,69095,diethylstilbestrol (5 mg) (for 84 days),surgical implantation, 1121,"Gould KA, et al., Mamm Genome. 2006 May;17(5):451-64.",thymus mass,,RS:0000032,ACI/SegHsd,male,147 days,13,,CMO:0000855,thymus wet weight,,,,166,mg,6.1017,22.0,MMO:0000005,post excision weight measurement,,0.0,diethylstilbestrol,subcutaneous implant,84,days,diethylstilbestrol (5 mg) (for 84 days) and surgical implantation,69099,diethylstilbestrol (5 mg) (for 84 days),surgical implantation, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0001297,F344.BN-(D5Rat1-D5Mit5)/Dlw,not specified,91 days,6,,CMO:0001757,lactotroph count to total pituicyte count ratio in prolactinoma,,lactotroph to total pituicyte ratio,,86,%,9.0,22.0454,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69920,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1838,"Pandey J and Wendell DL, Mamm Genome. 2006 Jan;17(1):49-57. Epub 2006 Jan 13.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,female,91 days,N/A,,CMO:0001757,lactotroph count to total pituicyte count ratio in prolactinoma,,,,99.1,%,,,MMO:0000538,ex vivo light microscopy with immunohistochemistry,,0.0,,subcutaneous implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),97077,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 1838,"Pandey J and Wendell DL, Mamm Genome. 2006 Jan;17(1):49-57. Epub 2006 Jan 13.",pituitary gland integrity trait,,RS:0000273,F344.BN-(D3Mgh13-D3Mgh7)/Dlw,female,91 days,N/A,,CMO:0001757,lactotroph count to total pituicyte count ratio in prolactinoma,,,,93.4,%,,,MMO:0000538,ex vivo light microscopy with immunohistochemistry,,0.0,,subcutaneous implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),97079,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days), 331,"Shull JD, et al., Mamm Genome. 2007 Sep 18;.",pituitary gland mass,,RS:0000155,BN/SsNHsd,female,266 days to 252 days,10,,CMO:0002168,binary logarithm of pituitary gland wet weight,,logarithm of pituitary wet weight,,3.79,,0.0664,0.21,MMO:0000005,post excision weight measurement,pituitary gland,0,,,,,surgical implantation then 17 beta-estradiol (27.5 mg) (between 193 and 199 days),65768,surgical implantation,,17 beta-estradiol (27.5 mg) (between 193 and 199 days) 331,"Shull JD, et al., Mamm Genome. 2007 Sep 18;.",pituitary gland mass,,RS:0000032,ACI/SegHsd,female,266 days to 252 days,9,,CMO:0002168,binary logarithm of pituitary gland wet weight,,logarithm of pituitary wet weight,,7.15,,0.12,0.36,MMO:0000005,post excision weight measurement,pituitary gland,0,,,,,surgical implantation then 17 beta-estradiol (27.5 mg) (between 193 and 199 days),65770,surgical implantation,,17 beta-estradiol (27.5 mg) (between 193 and 199 days)